MAPT and Alzheimer disease: This framework was revised and updated in the 2024 Alzheimer's Association guidelines for Alzheimer ́s disease diagnosis and staging [5], according to which abnormalities of any “core 1” biomarker – such as markers of amyloid-β (Aβ) proteinopathy or soluble phosphorylated-tau (p-tau) – are sufficient to establish a biological diagnosis of AD, regardless of the presence of clinical symptoms.